European Meeting on HIV & Hepatitis 2022

Characterization of SARS-CoV-2 Epidemic and Transmission Dynamics in Children Over the Four COVID-19 Waves

Slideset

HIV

Viral Hepatitis and Liver Disease

Circulation of SARS-CoV-2 Variants in Central Italy: Spike Variability Characterization by Deep-Sequencing (#2)

Slideset

HIV

Viral Hepatitis and Liver Disease

Impact of Sars-Cov-2 Omicron and Delta Sub-Lineage AY.4.2 Variant on Neutralization by Sera of Patients Treated With Different Licensed Monoclonal Antibodies

Slideset

HIV

Viral Hepatitis and Liver Disease

Levels and Durability of Humoral and T-Specific Responses After the Booster Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility

Slideset

HIV

Viral Hepatitis and Liver Disease

Country Experiences: Western Europe / France

Slideset

HIV

Viral Hepatitis and Liver Disease

Country Experiences: Eastern Europe / Czech Republic

Slideset

HIV

Viral Hepatitis and Liver Disease

Country Experiences: Northern Europe / Sweden

Slideset

HIV

Viral Hepatitis and Liver Disease

Country Experiences: Southern Europe / Italy

Slideset

HIV

Viral Hepatitis and Liver Disease

The Top 10 Important Observations Last Year

Slideset

HIV

Viral Hepatitis and Liver Disease

New Antiretroviral Compounds: What Are the Resistance Concerns?

Slideset

HIV

Viral Hepatitis and Liver Disease

New Antiretroviral Compounds: What Are the Resistance Concerns?

Slideset

HIV

Viral Hepatitis and Liver Disease

Transmitted Drug Resistance to Integrase Based First-Line Treatment in Europe, 2018-2021

Slideset

HIV

Viral Hepatitis and Liver Disease

HIV Transmission Clusters in Europe: A Perspective View of Late Presenters and Non-Late Presenters

Slideset

HIV

Viral Hepatitis and Liver Disease

Implementing LA-ARVs in Europe: Which Patient? Which Formulation?

Slideset

HIV

Viral Hepatitis and Liver Disease

Implementing LA-ARVs in Europe: Which Patient? Which Formulation?

Slideset

HIV

Viral Hepatitis and Liver Disease

European Meeting on HIV & Hepatitis 2022

Impact of Variants on Clinical Presentation and Outcome in Severe COVID Disease

Early Clinical Phase - Monoclonal Antibodies

Early Clinical Phase - Antiviral Drugs

Special Lecture: Current Outbreaks of Concern

Characterization of SARS-CoV-2 Epidemic and Transmission Dynamics in Children Over the Four COVID-19 Waves

Circulation of SARS-CoV-2 Variants in Central Italy: Spike Variability Characterization by Deep-Sequencing (#2)

Impact of Sars-Cov-2 Omicron and Delta Sub-Lineage AY.4.2 Variant on Neutralization by Sera of Patients Treated With Different Licensed Monoclonal Antibodies

Levels and Durability of Humoral and T-Specific Responses After the Booster Dose of mRNA BNT162b2 Vaccine in Residents of a Long Term Care Facility

Country Experiences: Western Europe / France

Country Experiences: Eastern Europe / Czech Republic

Country Experiences: Northern Europe / Sweden

Country Experiences: Southern Europe / Italy

The Top 10 Important Observations Last Year

New Antiretroviral Compounds: What Are the Resistance Concerns?

New Antiretroviral Compounds: What Are the Resistance Concerns?

Transmitted Drug Resistance to Integrase Based First-Line Treatment in Europe, 2018-2021

HIV Transmission Clusters in Europe: A Perspective View of Late Presenters and Non-Late Presenters

Implementing LA-ARVs in Europe: Which Patient? Which Formulation?

Implementing LA-ARVs in Europe: Which Patient? Which Formulation?

HIV Care and War in Ukraine